AsclepiX Therapeutics Inc. is a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis that is disrupted in retinal and oncologic diseases. The novel clinical candidate peptides discovered by AsclepiX tap into these naturally existing self-regulating mechanisms, evolved over millions of years, that the body uses to maintain homeostasis and thus restore and maintain health. AXT107, an investigational product and the lead clinical candidate, has a unique mechanism of action that targets two clinically proven pathways of diseases of the retina. AXT107 is poised to enter the clinic in late 2020.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/24/20 | $35,000,000 | Series A |
Perceptive Advisors Rapha Capital Management | undisclosed |
